首页> 外文期刊>Internal medicine. >An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin
【24h】

An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin

机译:丙型肝炎病毒(HCV)/ HIV合并感染的患者,在慢性HCV感染期间发展为严重的肝炎:使用Simeprevir加上Peginterferon-Alpha和Ribavirin的持续病毒应答

获取原文
           

摘要

We herein describe the case of a 42-year-old man who developed severe hepatitis caused by hepatitis C virus (HCV) infection at 14 years after the start of human immunodeficiency virus (HIV) treatment. Surprisingly, the levels of alanine aminotransferase (ALT) fluctuated, reaching a peak higher than 1,000 IU/L during chronic HCV infection, and the hepatic histology showed advanced liver fibrosis at 3 years after the primary HCV infection. He was treated with simeprevir, peginterferon-alpha, and ribavirin with a sustained viral response. We conclude that HCV/HIV co-infected patients need to commence anti-HCV therapy when the levels of ALT fluctuate severely under successful HIV control.
机译:我们在本文中描述了一名42岁的男性患者,该患者在开始人类免疫缺陷病毒(HIV)治疗后14年发展为由丙型肝炎病毒(HCV)感染引起的严重肝炎。出乎意料的是,丙氨酸氨基转移酶(ALT)的水平波动,在慢性HCV感染期间达到高于1,000 IU / L的峰值,并且在原发性HCV感染后3年,肝脏组织学显示晚期肝纤维化。他接受了simeprevir,peginterferon-alpha和利巴韦林的治疗,具有持续的病毒反应。我们得出结论,在成功控制HIV的情况下,如果ALT的水平剧烈波动,则HCV / HIV合并感染的患者需要开始抗HCV治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号